Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Enriched-enrollment, Randomized-withdrawal, Double-blinded, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Intranasal Oxytocin in Subjects With Chronic Migraine

NCT01839149 is registered in ClinicalTrials.gov with Trigemina, Inc as lead sponsor.

NCT NCT01839149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01839149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Enriched-enrollment, Randomized-withdrawal, Double-blinded, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Intranasal Oxytocin in Subjects With Chronic Migraine
Lead sponsor
Trigemina, Inc
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2013
Completion date
January 31, 2016
Enrollment
240 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

high frequency episodic migraine and chronic migraine